• 1
    Guillaume S, Prieur AM, Coste J, Job-Deslandre C. Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum 2000; 43: 185865.
  • 2
    Cassidy JT, Petty RE. Oligoarthritis. In: CassidyJT, PettyRE, editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: WB Saunders; 2005. p. 27490.
  • 3
    Oen KG, Cheang M. Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 1996; 26: 57591.
  • 4
    Minden K, Kiessling U, Listing J, Niewerth M, Doring E, Meincke J, et al. Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 2000; 27: 225663.
  • 5
    Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999; 42: 23304.
  • 6
    Selvaag AM, Flato B, Dale K, Lien G, Vinje O, Smerdel-Ramoya A, et al. Radiographic and clinical outcome in early juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3-year prospective study. J Rheumatol 2006; 33: 138291.
  • 7
    Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294: 167184.
  • 8
    Beukelman T, Guevara JP, Albert DA, Sherry DD, Burnham JM. Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. J Rheumatol 2007; 34: 191824.
  • 9
    Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 162432.
  • 10
    Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis. Part 1. Getting started. Med Decis Making 1997; 17: 1235.
  • 11
    Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. 2nd ed. New York: Oxford University Press; 2000.
  • 12
    Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis. Part 5. Working with Markov processes. Med Decis Making 1997; 17: 1529.
  • 13
    Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 32238.
  • 14
    Chapman GB, Elstein AS, Kuzel TM, Nadler RB, Sharifi R, Bennett CL. A multi-attribute model of prostate cancer patient's preferences for health states. Qual Life Res 1999; 8: 17180.
  • 15
    Schapira MM, Gilligan MA, McAuliffe TL, Nattinger AB. Menopausal hormone therapy decisions: insights from a multi-attribute model. Patient Educ Couns 2004; 52: 8995.
  • 16
    Gold MR, Patrick DL, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS, et al. Identifying and valuing outcomes. In: GoldMR, SiegelJE, RussellLB, WeinsteinMC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. p. 82123.
  • 17
    Froberg DG, Kane RL. Methodology for measuring health-state preferences. I. Measurement strategies. J Clin Epidemiol 1989; 42: 34554.
  • 18
    Skeith KJ, Jamali F. Clinical pharmacokinetics of drugs used in juvenile arthritis. Clin Pharmacokinet 1991; 21: 12949.
  • 19
    Zulian F, Martini G, Gobber D, Agosto C, Gigante C, Zacchello F. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2003; 42: 12549.
  • 20
    Eberhard BA, Sison MC, Gottlieb BS, Ilowite NT. Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 250712.
  • 21
    Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 2004; 43: 128891.
  • 22
    Honkanen VE, Rautonen JK, Pelkonen PM. Intra-articular glucocorticoids in early juvenile chronic arthritis. Acta Paediatr 1993; 82: 10724.
  • 23
    Breit W, Frosch M, Meyer U, Heinecke A, Ganser G. A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 2000; 27: 2696702.
  • 24
    Lovell DJ, Giannini EH, Brewer EJ Jr. Time course of response to nonsteroidal antiinflammatory drugs in juvenile rheumatoid arthritis. Arthritis Rheum 1984; 27: 14337.
  • 25
    Padeh S, Passwell JH. Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum 1998; 41: 12104.
  • 26
    Smith J, Scuccimarri R, Gibbon M, Yang H, Platt R, Watanabe-Duffy K, et al. Efficacy of intra-articular triamcinolone hexacetonide in a practice-based cohort of children with juvenile arthritis [abstract]. J Rheumatol 2000; 27 Suppl 58: 95.
  • 27
    Swan JS, Fryback DG, Lawrence WF, Sainfort F, Hagenauer ME, Heisey DM. A time-tradeoff method for cost-effectiveness models applied to radiology. Med Decis Making 2000; 20: 7988.
  • 28
    Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Oper Res 1982; 30: 104369.
  • 29
    Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24: 104353.
  • 30
    Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res 1972; 7: 11833.
  • 31
    Stevens SS. Issues in psychophysical measurement. Psychol Rev 1971; 78: 42650.
  • 32
    Allen RC, Gross KR, Laxer RM, Malleson PN, Beauchamp RD, Petty RE. Intraarticular triamcinolone hexacetonide in the management of chronic arthritis in children. Arthritis Rheum 1986; 29: 9971001.
  • 33
    Lepore L, Del Santo M, Malorgio C, Presani G, Perticarari S, Prodan M, et al. Treatment of juvenile idiopathic arthritis with intra-articular triamcinolone hexacetonide: evaluation of clinical effectiveness correlated with circulating ANA and T gamma/delta + and B CD5+ lymphocyte populations of synovial fluid. Clin Exp Rheumatol 2002; 20: 71922.
  • 34
    Ravelli A, Manzoni SM, Viola S, Pistorio A, Ruperto N, Martini A. Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis. J Rheumatol 2001; 28: 21002.
  • 35
    Brewer EJ, Giannini EH, Baum J, Cassidy JT, Fink CW, Hanson V, et al. Sodium meclofenamate (Meclomen) in the treatment of juvenile rheumatoid arthritis: a segment I study. J Rheumatol 1982; 9: 12934.
  • 36
    Brik R, Gepstein V, Berkovitz D. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids. Clin Rheumatol 2005; 24: 6124.
  • 37
    Brewer EJ, Giannini EH, Baum J, Bernstein B, Fink CW, Schaller JG, et al. Ketoprofen (Orudis) in the treatment of juvenile rheumatoid arthritis: a segment I study. J Rheumatol 1982; 9: 1448.
  • 38
    Brewer EJ, Giannini EH, Baum J, Fink CW, Hanson V, Jacobs JC, et al. Proquazone (Biarsan) in the treatment of juvenile rheumatoid arthritis: a segment I study. J Rheumatol 1982; 9: 1359.
  • 39
    Bass JC, Giannini EH, Brewer EJ, Athreya BH, Brandstrup NE, Goldsmith DP, et al. Pirprofen (Rengasil) in the treatment of juvenile rheumatoid arthritis: a segment I study. J Rheumatol 1982; 9: 1403.
  • 40
    Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum 2005; 52: 56372.
  • 41
    Brewer EJ, Giannini EH, Baum J, Bernstein B, Fink CW, Emery HM, et al. Aspirin and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis results of the double blind-trial: a segment II study. J Rheumatol 1982; 9: 1238.
  • 42
    Kvien TK, Hoyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis: assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study. Scand J Rheumatol 1984; 13: 34250.
  • 43
    Hertzberger-ten Cate R, de Vries-van der Vlugt BC, van Suijlekom-Smit LW, Cats A. Intra-articular steroids in pauciarticular juvenile chronic arthritis, type 1. Eur J Pediatr 1991; 150: 1702.
  • 44
    Earley A, Cuttica RJ, McCullough C, Ansell BM. Triamcinolone into the knee joint in juvenile chronic arthritis. Clin Exp Rheumatol 1988; 6: 1535.
  • 45
    Balogh Z, Ruzsonyi E. Triamcinolone hexacetonide versus betamethasone. A double-blind comparative study of the long-term effects of intra-articular steroids in patients with juvenile chronic arthritis. Scand J Rheumatol Suppl 1987; 67: 802.
  • 46
    Yang MH, Lee WI, Chen LC, Lin SJ, Huang JL. Intraarticular triamcinolone hexacetonide injection in children with chronic arthritis: a survey of clinical practice. Acta Paediatr Taiwan 1999; 40: 1825.
  • 47
    Job-Deslandre C, Menkes CJ. Complications of intra-articular injections of triamcinolone hexacetonide in chronic arthritis in children. Clin Exp Rheumatol 1990; 8: 4136.
  • 48
    Reiff A, Lovell DJ, Adelsberg JV, Kiss MH, Goodman S, Zavaler MF, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol 2006; 33: 98595.
  • 49
    Goodman S, Howard P, Haig A, Flavin S, Macdonald B. An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthritis. J Rheumatol 2003; 30: 82931.
  • 50
    Ailioaie C, Lupusoru-Ailioaie LM. Antirheumatic effects of first-line agents in the treatment of juvenile chronic arthritis. Rev Med Chir Soc Med Nat Iasi 1997; 101: 1348.
  • 51
    Giannini EH, Brewer EJ, Miller ML, Gibbas D, Passo MH, Hoyeraal HM, et al, and the Pediatric Rheumatology Collaborative Study Group. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. J Pediatr 1990; 117: 64552.
  • 52
    Leak AM, Richter MR, Clemens LE, Hall MA, Ansell BM. A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol 1988; 6: 15760.
  • 53
    Laxer RM, Silverman ED, St-Cyr C, Tran MT, Lingam G. A six-month open safety assessment of a naproxen suspension formulation in the therapy of juvenile rheumatoid arthritis. Clin Ther 1988; 10: 3817.
  • 54
    Garcia-Morteo O, Maldonado-Cocco JA, Cuttica R, Garay SM. Piroxicam in juvenile rheumatoid arthritis. Eur J Rheumatol Inflamm 1987; 8: 4953.
  • 55
    Williams PL, Ansell BM, Bell A, Cain AR, Chamberlain MA, Clarke AK, et al. Multicentre study of piroxicam versus naproxen in juvenile chronic arthritis, with special reference to problem areas in clinical trials of nonsteroidal anti-inflammatory drugs in childhood. Br J Rheumatol 1986; 25: 6771.
  • 56
    Haapasaari J, Wuolijoki E, Ylijoki H. Treatment of juvenile rheumatoid arthritis with diclofenac sodium. Scand J Rheumatol 1983; 12: 32530.
  • 57
    Bhettay E, Thomson AJ. Double-blind study of ketoprofen and indomethacin in juvenile chronic arthritis. S Afr Med J 1978; 54: 2768.
  • 58
    Levinson JE, Baum J, Brewer E, Jr., Fink C, Hanson V, Schaller J. Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid arthritis. J Pediatr 1977; 91: 799804.
  • 59
    Bass J, Athreya B, Brandstrup N, Brewer E, Di Ianni M, Goldsmith D, et al. Flurbiprofen in the treatment of juvenile rheumatoid arthritis. J Rheumatol 1986; 13: 10813.
  • 60
    Price T, Venning H, Ansell BM. Indoprofen in juvenile chronic arthritis. Clin Exp Rheumatol 1985; 3: 5962.
  • 61
    Nicholls A, Hazleman B, Todd RM, Murray-Leslie C, Kuhnen H, Cain AR. Long-term evaluation of naproxen suspension in juvenile chronic arthritis. Curr Med Res Opin 1982; 8: 2047.
  • 62
    Moran H, Hanna DB, Ansell BM, Hall M, Engler C. Naproxen in juvenile chronic polyarthritis. Ann Rheum Dis 1979; 38: 1524.
  • 63
    Dowd JE, Cimaz R, Fink CW. Nonsteroidal antiinflammatory drug–induced gastroduodenal injury in children. Arthritis Rheum 1995; 38: 122531.
  • 64
    Ashorn M, Verronen P, Ruuska T, Huhtala H. Upper endoscopic findings in children with active juvenile chronic arthritis. Acta Paediatr 2003; 92: 55861.
  • 65
    Weber P, Brune T, Ganser G, Zimmer KP. Gastrointestinal symptoms and permeability in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2003; 21: 65762.
  • 66
    Flato B, Vinje O, Forre O. Toxicity of antirheumatic and anti-inflammatory drugs in children. Clin Rheumatol 1998; 17: 50510.
  • 67
    Len C, Hilario MO, Kawakami E, Terreri MT, Becker DJ, Goldenberg J, et al. Gastroduodenal lesions in children with juvenile rheumatoid arthritis. Hepatogastroenterology 1999; 46: 9916.
  • 68
    Duffy CM, Gibbon M, Yang H, Watanabe-Duffy KN, Taylor G, Platt R. Non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity in a practice-based cohort of children with juvenile arthritis [abstract]. J Rheumatol 2000; 27 Suppl 58: 73.
  • 69
    Hollander JL. Intrasynovial corticosteroid therapy in arthritis. Md State Med J 1970; 19: 626.
  • 70
    Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1981; 10: 23154.
  • 71
    Ostensson A, Geborek P. Septic arthritis as a non-surgical complication in rheumatoid arthritis: relation to disease severity and therapy. Br J Rheumatol 1991; 30: 358.
  • 72
    Pal B, Morris J. Perceived risks of joint infection following intra-articular corticosteroid injections: a survey of rheumatologists. Clin Rheumatol 1999; 18: 2645.
  • 73
    Kendall PH. Local corticosteroid injection therapy. III. Ann Phys Med 1963; 7: 318.
  • 74
    Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen: a practitioner-based randomized clinical trial. JAMA 1995; 273: 92933.
  • 75
    Keenan GF, Giannini EH, Athreya BH. Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol 1995; 22: 114951.
  • 76
    Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 2419.
  • 77
    Szer IS, Goldenstein-Schainberg C, Kurtin PS. Paucity of renal complications associated with nonsteroidal antiinflammatory drugs in children with chronic arthritis. J Pediatr 1991; 119: 8157.
  • 78
    Haftel HM, Mitchell JM, Adams BS. Incidence of renal toxicity from anti-inflammatory medications in a pediatric rheumatology population: role of routine screening of urine [abstract]. J Rheumatol 2000; 27 Suppl 58: 73.
  • 79
    Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol Suppl 1992; 33: 610.
  • 80
    Riddle R, Ryser CN, Morton AA, Sampson JD, Browne RH, Punaro MG, et al. The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis. J Pediatr Psychol 2006; 31: 26271.
  • 81
    Beukelman T, Arabshahi B, Cahill AM, Kaye RD, Cron RQ. Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis. J Rheumatol 2006; 33: 23306.
  • 82
    Beukelman T, Guevara JP, Albert DA, Sherry DD, Burnham JM. Usage of intra-articular corticosteroid injections for the treatment of juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. Clin Exp Rheumatol 2008; 26: 7003.
  • 83
    Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 22904.
  • 84
    Giles JT, Mease P, Boers M, Bresnihan B, Conaghan PG, Heald A, et al. Assessing single joints in arthritis clinical trials. J Rheumatol 2007; 34: 6417.
  • 85
    Bennett JE, Sumner W 2nd, Downs SM, Jaffe DM. Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med 2000; 154: 438.
  • 86
    Prosser LA, Ray GT, O'Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 2004; 113: 28390.
  • 87
    Madsen KA, Bennett JE, Downs SM. The role of parental preferences in the management of fever without source among 3- to 36-month-old children: a decision analysis. Pediatrics 2006; 117: 106776.